Multiple Sclerosis Clinical Trial
Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)
Summary
This study will evaluate the safety and efficacy of OnabotulinumtoxinA (BOTOX®) for the treatment of urinary incontinence due to NDO in non-catheterizing patients with MS.
Eligibility Criteria
Inclusion Criteria:
At least 3 episodes of urinary incontinence over a 3-day period
History of Multiple Sclerosis (MS)
Urinary incontinence not adequately controlled by anticholinergic medication
Exclusion Criteria:
Current use of intermittent catheter or indwelling catheter to manage urinary incontinence
Previous or current botulinum toxin therapy of any serotype for any urological condition
Previous or current botulinum toxin therapy of any serotype for any non-urological condition within the last 12 weeks
Diagnosis of myasthenia gravis, Eaton-Lambert Syndrome, or Amyotrophic Lateral Sclerosis
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Mountlake Terrace Washington, , United States
Liege , , Belgium
Victoria British Columbia, , Canada
Kitchener Ontario, , Canada
Olomouc , , Czechia
Garches , , France
Marseille , , France
Warsaw , , Poland
Porto , , Portugal
St. Petersburg , , Russian Federation
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.